Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dicot Pharma ABFRA:KN0 -5.47%20 14-Day RSI is 49.32 as of Aug. 11, 2026. GuruFocus rates FRA:KN0 with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 1,046 Drug Manufacturers companies, Dicot Pharma AB ranks better than 60.13% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-08-11), Dicot Pharma AB's 14-Day RSI is 49.32.
The industry rank for Dicot Pharma AB's 14-Day RSI or its related term are showing as below:
FRA:KN0's 14-Day RSI is ranked better than 60.13% of 1046
companies
in the Drug Manufacturers industry
Industry Median: 53.355
vs FRA:KN0: 49.32
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Dicot Pharma AB 14-Day RSI Related Terms
FRA:KN0 vs ZTS: 14-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dicot Pharma AB's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dicot Pharma AB 14-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dicot Pharma AB's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Dicot Pharma AB's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dicot Pharma AB (FRA:KN0) has a 14-Day RSI of 49.32 as of Aug. 11, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Dicot Pharma AB and its competitors. According to the industry distribution chart, Dicot Pharma AB ranks #417 out of 1046 companies in the Drug Manufacturers industry, placing it in the top 39.9%.
Is Dicot Pharma AB's 14-Day RSI too high?
Dicot Pharma AB's current 14-Day RSI is 49.32. The Drug Manufacturers industry median 14-Day RSI is 53.36. Dicot Pharma AB's value of 49.32 is 7.6% below this industry median. Based on the distribution chart, Dicot Pharma AB ranks #417 out of 1046 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Dicot Pharma AB has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Dicot Pharma AB's 14-Day RSI compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Dicot Pharma AB ranks #417 out of 1046 companies for 14-Day RSI. This puts Dicot Pharma AB in the upper half of its industry. The industry median 14-Day RSI is 53.36. Dicot Pharma AB's value of 49.32 is 7.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Drug Manufacturers company?
The median 14-Day RSI among Drug Manufacturers companies is 53.36, based on 1,046 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dicot Pharma AB's current 14-Day RSI of 49.32 is 7.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Dicot Pharma AB and its competitors. For the Drug Manufacturers industry, the median 14-Day RSI is 53.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dicot Pharma AB's current 14-Day RSI is 49.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dicot Pharma AB stock overvalued right now?
Dicot Pharma AB (FRA:KN0) has a current 14-Day RSI of 49.32. The current 14-Day RSI is 49.32 and 7.6% below the Drug Manufacturers industry median of 53.36. Dicot Pharma AB's overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Dicot Pharma AB (FRA:KN0), the current 14-Day RSI is 49.32 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dicot Pharma AB is developing a modern potency medicine that will treat erectile dysfunction and premature ejaculation than existing preparations. The business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market. The company's drug candidate LIB-01 has a longer duration of action and fewer side effects, and is also used in the treatment of erectile dysfunction and premature ejaculation.
20GF Score
Get the complete analysis for FRA:KN0
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:KN0 has been successfully added to your 
